If your plan won't cover a GLP-1 and you don't want a compounded copy, there's a third door that is fairly new: buying the brand-name medication straight from the company that makes it, at a flat cash price. Eli Lilly launched LillyDirect in January 2024, and Novo Nordisk opened NovoCare Pharmacy in March 2025. The two work similarly enough to be confused and differently enough to matter. This guide covers what each one is and what it can and can't do for you.
What "manufacturer direct-pay" means
Both programs are self-pay pharmacies operated by the drugmaker. You still need a prescription from a licensed clinician, and the product that arrives is the same FDA-approved brand medication a retail pharmacy would dispense, not a compounded version. What's different is the payment path: instead of running through your insurance and a pharmacy benefit manager, you pay the manufacturer a set price and the medication ships to your door.
LillyDirect sells Lilly's own products, most notably Zepbound (tirzepatide) for weight management and, since April 2026, the Foundayo (orforglipron) pill. NovoCare Pharmacy sells Novo Nordisk's, including Wegovy (semaglutide) for weight management and Ozempic (semaglutide) pens and tablets for type 2 diabetes. In both cases your prescriber sends the script to the manufacturer's pharmacy, you set up an account and pay, and you choose delivery or pickup.
Our broader guide to pharmacy sources for GLP-1 medications covers direct-pay alongside compounded and telehealth options. This guide looks only at the two manufacturer channels.
The single-dose vial vs. pen distinction
The detail that made direct-pay newsworthy was the single-dose vial. The familiar format is a prefilled pen or autoinjector: you dial a dose and inject, needle included. A single-dose vial is a small glass container holding one week's dose, from which you draw the medication yourself using a separate syringe and needle you have to obtain and handle correctly.
Lilly leaned into vials to hit lower price points. As of September 2026, LillyDirect's self-pay Zepbound vials run about $299/month for the 2.5 mg starting dose, $399 for 5 mg, and $449 for the 7.5 mg through 15 mg maintenance doses, and Lilly now prices its Zepbound KwikPen at the same tiers. Those maintenance prices depend on refilling within 45 days of your last delivery; outside that window the price reverts higher (Lilly lists roughly $499–$699). This LillyDirect cash pricing is a different thing from the Zepbound savings card's "non-covered" tier, which is for people who have commercial insurance that excludes Zepbound and discounts the single-dose pen to about $499/month or the KwikPen to $299–$449/month by dose. Novo's self-pay uses pens and tablets and has no vials. Lilly's Foundayo pill is also sold self-pay through LillyDirect. Lilly announced self-pay pricing starting at $149 a month for the lowest dose when it launched the pill in April 2026, and as of September 2026 Lilly's Foundayo pricing pages list up to $349 a month for the highest doses.
The vial is cheaper and sometimes easier to get, but it asks more of you: measuring the dose, managing sharps, and following instructions precisely. FDA has received reports of dosing errors, some needing hospital care, when patients measured their own doses of compounded injectable semaglutide. Those were compounded products, not brand vials, but they show why drawing up a dose takes careful technique.
Savings card vs. cash pay
Both companies offer "pay as little as $X" figures, and it's easy to conflate two different mechanisms.
A savings card (sometimes called a copay card) lowers what you pay when you do have commercial insurance. It knocks down your copay, usually with a monthly cap on how much it covers, and typically excludes anyone on Medicare, Medicaid, or other government coverage. NovoCare, for instance, advertises a savings offer bringing eligible commercially insured patients to as little as $25/month up to a set cap. Our side-by-side guide to every GLP-1 savings card covers the current terms, caps, and eligibility for each drug.
Cash self-pay is a flat price you pay when insurance isn't in the picture at all: you're uninsured, or your plan excludes the drug. That's the LillyDirect pricing above, plus NovoCare's self-pay prices. As of September 2026, the Wegovy pen starts at about $199 for introductory doses and steps up to higher monthly prices, with the oral tablet from $149. The Ozempic pen is $199 a month for new patients on the 0.25 mg and 0.5 mg doses, then $349 a month for 0.25–1 mg and $499 a month for 2 mg. Ozempic tablets, on sale since May 2026, are $149 (1.5 mg), $199 (4 mg), and $299 (9 mg) a month. Numbers, promotional windows, and eligibility rules change often. Treat these figures as snapshots, not quotes, and check the manufacturer's site for what applies to you today.
Who this actually helps
Direct-pay tends to make sense for a specific situation: you have no coverage for the drug (you're uninsured, or your plan excludes weight-management medication) and you want the genuine brand product rather than a compounded one. For those people it's often the cleanest legitimate cash route, because it ships from the manufacturer's own authorized channel with no question about what's in the vial.
It's less relevant if your insurance already covers the medication at a reasonable copay, since a covered brand prescription is usually cheaper than any cash price. If your denial is the problem, our guide to understanding insurance coverage walks through formularies, prior authorization, and appeals. Sometimes fixing the coverage beats paying cash.
What direct-pay doesn't solve
Neither program changes the underlying economics of the drug. Know the limits going in.
It's still brand pricing. A few hundred dollars a month is far below list price, but it's not cheap, and it's an ongoing cost for a medication most people take long-term. The lowest advertised numbers often attach to starting doses or limited-time offers, not the maintenance dose you'll settle on. If your income is low and you're uninsured or on Medicare, a manufacturer patient assistance program may be worth checking, though as of September 2026 neither company's program covers Wegovy, Zepbound, Saxenda, or Foundayo.
It doesn't override your insurance. Cash self-pay generally sits outside your plan, so what you spend usually doesn't count toward your deductible or out-of-pocket maximum, and savings cards exclude government-insured patients.
It doesn't guarantee supply or the diagnosis you want. Each product is sold for its own approved use. Zepbound and Mounjaro are the same molecule, but LillyDirect's self-pay prices above are for Zepbound (weight management) and Foundayo, and Mounjaro (type 2 diabetes) is a separate prescription. NovoCare prices Wegovy and Ozempic separately in the same way. Availability of particular doses or formats can also shift.
The core question is narrow and answerable: do you have coverage, and do you want the brand product? If the answer is "no coverage" and "yes, brand," a manufacturer direct-pay pharmacy is likely your most straightforward legitimate option. If either answer flips, another route probably serves you better.
This is general information, not medical or financial advice. Prices, offers, and eligibility rules change constantly, so confirm the current specifics directly with the manufacturer's pharmacy and your care team before you count on any figure here.